776 related articles for article (PubMed ID: 7986116)
1. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
Kuroda M; Kotake T
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():362-9. PubMed ID: 7986116
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer.
Kuroda M; Meguro N; Maeda O; Saiki S; Kinouchi T; Usami M; Kotake T
Cancer Chemother Pharmacol; 1994; 35 Suppl():S9-13. PubMed ID: 7527736
[TBL] [Abstract][Full Text] [Related]
3. Can patient selection for bladder preservation be based on response to chemotherapy?
Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
7. [Current status of adjuvant chemotherapy of invasive bladder cancer].
Ozono S; Sasaki K; Watanabe S; Maruyama Y; Ohara S; Babaya K; Yamada K; Hirao Y; Okajima E
Hinyokika Kiyo; 1991 Dec; 37(12):1589-95. PubMed ID: 1785379
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
9. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for poor prognosis patients with urothelial tumors and effect of dose intensity.
Hibi H; Okamura K; Takashi M; Shimoji T; Miyake K
Hinyokika Kiyo; 1997 Feb; 43(2):89-96. PubMed ID: 9086342
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only.
de Vries RR; Nieuwenhuijzen JA; Meinhardt W; Bais EM; Horenblas S
Eur J Surg Oncol; 2009 Apr; 35(4):352-5. PubMed ID: 18722076
[TBL] [Abstract][Full Text] [Related]
11. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
[TBL] [Abstract][Full Text] [Related]
12. [Neoadjuvant chemotherapy for invasive bladder cancer].
Kageyama Y; Kihara K
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1838-44. PubMed ID: 11729476
[TBL] [Abstract][Full Text] [Related]
13. [Neoadjuvant chemotherapy (M-VAC) for locally invasive bladder cancer].
Kamoto T; Kawakita M; Okabe T; Matsumoto M; Matsuda T; Yoshida O
Hinyokika Kiyo; 1992 Apr; 38(4):405-11. PubMed ID: 1529813
[TBL] [Abstract][Full Text] [Related]
14. [Postoperative adjuvant M-VAC chemotherapy for invasive bladder cancer].
Yamashita S; Taniguchi K; Morimitsu H; Suzu H; Kanetake H; Saito Y; Yushita Y; Sakuragi T
Hinyokika Kiyo; 1992 May; 38(5):519-24. PubMed ID: 1609658
[TBL] [Abstract][Full Text] [Related]
15. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
[TBL] [Abstract][Full Text] [Related]
16. [Neoadjuvant chemotherapy in muscle-invasive bladder cancer].
Miyanaga N; Akaza H
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1745-9. PubMed ID: 18030008
[TBL] [Abstract][Full Text] [Related]
17. [The role of M-VAC polychemotherapy in the treatment of advanced urothelial carcinoma of the bladder].
Stöckle M; Meyenburg W; Wellek S; Voges G; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
Ann Urol (Paris); 1993; 27(1):51-7. PubMed ID: 7682388
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer.
Nieuwenhuijzen JA; Bex A; Meinhardt W; Kerst JM; Schornagel JH; VAN Tinteren H; Horenblas S
J Urol; 2005 Jul; 174(1):80-5. PubMed ID: 15947583
[TBL] [Abstract][Full Text] [Related]
19. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.
Lehmann J; Franzaring L; Thüroff J; Wellek S; Stöckle M
BJU Int; 2006 Jan; 97(1):42-7. PubMed ID: 16336326
[TBL] [Abstract][Full Text] [Related]
20. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers].
Takenaka A; Gotoh A; Hara I; Gohji K; Ogawa T; Arakawa S; Matsumoto O; Kamidono S; Hamami G; Itani A
Gan To Kagaku Ryoho; 1990 Sep; 17(9):1909-15. PubMed ID: 2393308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
